Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | SVP, Cancer Biology & Co-CSO | April 23, 2017 | April 25, 2017 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Chief Scientific Officer | March 05, 2024 | March 06, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OncoMed Pharmaceuticals Inc
Report date April 23, 2017 · Filed April 25, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,225 |
Reported balance
After 2017-04-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-04-23 · Grant · Acquired 20,000 · Balance 77,225 F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2: Includes 32,500 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2027-04-22 | Direct | 60,000 |
Reported balance
After 2017-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-04-23 · Grant · Acquired 60,000 · Balance 60,000 F3: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
F2: Includes 32,500 RSUs.
F3: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
Tenaya Therapeutics, Inc.
Report date March 05, 2024 · Filed March 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 245,346 |
Reported balance
After 2024-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-05 · Sale · Disposed 3,300 · Balance 245,346 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.01. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3: Includes 50,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023.
F2: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.01. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: Includes 50,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2024 Filed Mar 6, 2024 18:45 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 3,300 | $7.00 | $23,100.99 |
DisclosureSEC source: 0000950170-24-027442 · ownership.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 245,346 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.01. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 50,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 19:31 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 75,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000950170-24-021550 · ownership.xml · derivative · entry 2 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2034-02-22 F4 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 19:31 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-021550 · ownership.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 248,646 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on August 15, 2024, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 50,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 18:05 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 200 | $6.17 | $1,233.00 |
DisclosureSEC source: 0000950170-24-018222 · ownership.xml · nonDerivative · entry 2 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,146 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.17. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 18:05 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 6,369 | $5.31 | $33,813.02 |
DisclosureSEC source: 0000950170-24-018222 · ownership.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 236,346 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.13 to $6.07. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 37,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 16, 2024 Filed Feb 16, 2024 20:37 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 4,681 | $5.86 | $27,430.66 |
DisclosureSEC source: 0000950170-24-016673 · ownership.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,715 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $5.61 to $6.15. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 37,500 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 29, 2023 Filed Aug 29, 2023 18:59 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 7,243 | $4.26 | $30,855.18 |
DisclosureSEC source: 0001209191-23-047673 · doc4.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,396 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.11 to $4.36. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 48,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:34 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 4,007 | $3.81 | $15,266.67 |
DisclosureSEC source: 0001209191-23-046642 · doc4.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,639 F1 · kind: Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on February 15, 2023. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.76 to $3.87. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F3 · balance_after: Includes 48,750 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 18:48 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 175,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001209191-23-010887 · doc4.xml · derivative · entry 3 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2033-02-14 F6 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter until fully vested. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 18:48 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010887 · doc4.xml · nonDerivative · entry 2 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,646 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F4 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the total number of shares subject to the restricted stock unit award on each of August 15, 2023, February 15, 2024, August 15, 2024 and February 15, 2025. F5 · balance_after: Includes 60,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 18:48 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-010887 · doc4.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,646 F1 · security: Represents shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Tenaya Therapeutics, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. The restricted stock units will vest as to 1/8th of the total number of shares subject to the restricted stock unit award on the six month anniversary of the Transaction Date, and 1/8th of the total number of shares subject to the restricted stock unit award every six months thereafter until fully vested. F3 · balance_after: Includes 30,000 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 19:57 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | SaleCommon Stock | 1,353 | $10.13 | $13,705.89 |
DisclosureSEC source: 0001209191-22-026097 · doc4.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,646 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 12, 2022. F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $10.02 to $10.33. Reporting Person undertakes to provide Tenaya Therapeutics, Inc., any security holder of Tenaya Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 17:36 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 168,000 | $0.00 Strike: $15.19 | $0.00 |
DisclosureSEC source: 0001209191-22-010916 · doc4.xml · derivative · entry 1 Hoey Timothy · CIK 0001553333 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,000 Underlying: Common Stock · 168,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest as to 1/48th of the total number of shares subject to the option on the one (1) month anniversary of the Transaction Date and 1/48th of the total number of shares subject to the option on each monthly anniversary thereafter, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:13 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $3.73 | $0.00 |
DisclosureSEC source: 0001140361-17-016768 · doc1.xml · derivative · entry 2 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-04-22 F3 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 23, 2017 Filed Apr 25, 2017 18:13 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-016768 · doc1.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,225 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 32,500 RSUs. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:40 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 5,711 | $9.06 | $51,731.38 |
DisclosureSEC source: 0001140361-17-015047 · doc1.xml · nonDerivative · entry 2 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,225 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 2,000 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017. Read SEC document |
| April 04, 2017 Filed Apr 5, 2017 19:40 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 43 | $8.87 | $381.29 |
DisclosureSEC source: 0001140361-17-015047 · doc1.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,936 F1 · kind: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2 · balance_after: Includes 12,500 restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F3 · balance_after: Includes 2,000 shares acquired under the Issuer's Employee Stock Purchase Plan on February 28, 2017. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:07 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0001140361-17-000848 · doc1.xml · derivative · entry 4 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2027-01-02 F5 · derivative.exercise_date: The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:07 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,763 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001140361-17-000848 · doc1.xml · derivative · entry 3 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,763 shares Expires 2017-01-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F4 · derivative.exercise_date: The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:07 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 12,763 | $7.64 | $97,448.06 |
DisclosureSEC source: 0001140361-17-000848 · doc1.xml · nonDerivative · entry 2 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,979 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F3 · price: This transaction was executed in multiple trades in prices ranging from $7.55 to $7.845, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 27,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 19:07 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionCommon Stock | 12,763 | $1.43 | $18,251.09 |
DisclosureSEC source: 0001140361-17-000848 · doc1.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,742 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F2 · balance_after: Includes 27,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 18:21 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001140361-16-087300 · doc1.xml · derivative · entry 3 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,763 Underlying: Common Stock · 12,500 shares Expires 2017-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F4 · derivative.exercise_date: The option is fully vested and exercisable, subject to a limitation of 175,438 shares that can be issued to a single grantee in a 12-month period upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 18:21 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | SaleCommon Stock | 12,500 | $9.89 | $123,608.75 |
DisclosureSEC source: 0001140361-16-087300 · doc1.xml · nonDerivative · entry 2 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,979 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F3 · price: This transaction was executed in multiple trades in prices ranging from $9.65 to $10.05, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 12,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 18:21 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | Exercise / conversionCommon Stock | 12,500 | $1.43 | $17,875.00 |
DisclosureSEC source: 0001140361-16-087300 · doc1.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · SVP, Cancer Biology & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 21, 2016. F2 · balance_after: Includes 12,500 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Read SEC document |
| October 09, 2016 Filed Oct 11, 2016 21:43 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-082542 · doc1.xml · nonDerivative · entry 1 Hoey Timothy · CIK 0001553333 · SVP & Co-CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,979 F1 · shares: Restricted stock units ("RSUs"). The reporting person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 27,500 restricted stock units and 1,298 shares acquired under the Issuer's Employee Stock Purchase Plan on February 29, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.